Literature DB >> 15078167

SIR2: the biochemical mechanism of NAD(+)-dependent protein deacetylation and ADP-ribosyl enzyme intermediates.

Anthony A Sauve1, Vern L Schramm.   

Abstract

The Sir2 family of enzymes is a recently described class of NAD(+)-dependent protein deacetylases that use NAD+ as a reactant to deacetylate acetyllysine residues of protein substrates to form the aminolysine sidechain and a novel product 2'-O-acetyl-ADP-ribose. The founding member of the Sir2 proteins, the yeast Sir2p, has been identified as a key member of SIR complexes responsible for the long-term silencing of genes in the yeast Saccharomyces cerevisiae. Increase of Sir2 activity by caloric restriction or osmotic stress increases genome stability and lifespan in this organism. The Sir2 reaction mechanism couples ADP-ribosyltransfer and hydrolysis reactions via the formation of a stabilized ADPR-peptidyl intermediate. Principles of the chemistry of stabilized ADPR intermediates are examined for Sir2 and the mechanistically related ADP-ribosylcyclase CD38. An examination of the crystal structures of Sir2 family members is presented with a view to the chemical requirements of the Sir2 reaction. The present review describes the current knowledge of the Sir2 reaction, the reaction mechanism and the regulation of Sir2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078167     DOI: 10.2174/0929867043455675

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  21 in total

1.  A mechanism-based potent sirtuin inhibitor containing Nε-thiocarbamoyl-lysine (TuAcK).

Authors:  Brett M Hirsch; Yujun Hao; Xiaopeng Li; Chrys Wesdemiotis; Zhenghe Wang; Weiping Zheng
Journal:  Bioorg Med Chem Lett       Date:  2011-06-22       Impact factor: 2.823

Review 2.  Sirtuin 1 and sirtuin 3: physiological modulators of metabolism.

Authors:  Ruben Nogueiras; Kirk M Habegger; Nilika Chaudhary; Brian Finan; Alexander S Banks; Marcelo O Dietrich; Tamas L Horvath; David A Sinclair; Paul T Pfluger; Matthias H Tschöp
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

Review 3.  Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?

Authors:  Paul O Hassa; Sandra S Haenni; Michael Elser; Michael O Hottiger
Journal:  Microbiol Mol Biol Rev       Date:  2006-09       Impact factor: 11.056

Review 4.  CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions.

Authors:  Eduardo Nunes Chini
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 5.  Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes.

Authors:  Carles Cantó; Anthony A Sauve; Peter Bai
Journal:  Mol Aspects Med       Date:  2013-01-25

6.  Crystal structures of human SIRT3 displaying substrate-induced conformational changes.

Authors:  Lei Jin; Wentao Wei; Yaobin Jiang; Hao Peng; Jianhua Cai; Chen Mao; Han Dai; Wendy Choy; Jean E Bemis; Michael R Jirousek; Jill C Milne; Christoph H Westphal; Robert B Perni
Journal:  J Biol Chem       Date:  2009-06-16       Impact factor: 5.157

7.  SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease.

Authors:  Saravanan Rajendrasozhan; Se-Ran Yang; Vuokko L Kinnula; Irfan Rahman
Journal:  Am J Respir Crit Care Med       Date:  2008-01-03       Impact factor: 21.405

8.  Activation of SIRT1 by resveratrol represses transcription of the gene for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) by deacetylating hepatic nuclear factor 4alpha.

Authors:  Jianqi Yang; Xiaoying Kong; Maria Emilia S Martins-Santos; Gabriela Aleman; Ernestine Chaco; George E Liu; Shwu-Yuan Wu; David Samols; Parvin Hakimi; Cheng-Ming Chiang; Richard W Hanson
Journal:  J Biol Chem       Date:  2009-08-03       Impact factor: 5.157

9.  SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1.

Authors:  Michelle Pacholec; John E Bleasdale; Boris Chrunyk; David Cunningham; Declan Flynn; Robert S Garofalo; David Griffith; Matt Griffor; Pat Loulakis; Brandon Pabst; Xiayang Qiu; Brian Stockman; Venkataraman Thanabal; Alison Varghese; Jessica Ward; Jane Withka; Kay Ahn
Journal:  J Biol Chem       Date:  2010-01-08       Impact factor: 5.157

10.  Covalent and noncovalent intermediates of an NAD utilizing enzyme, human CD38.

Authors:  Qun Liu; Irina A Kriksunov; Hong Jiang; Richard Graeff; Hening Lin; Hon Cheung Lee; Quan Hao
Journal:  Chem Biol       Date:  2008-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.